PBAM(PBAM)
PBAM
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E |
|---|---|---|
| Revenue Avg | $140M | $151M |
| Low | $139M | $148M |
| High | $142M | $155M |
| EBITDA Avg | $57M | $62M |
| Low | $57M | $60M |
| High | $58M | $63M |
| EBIT Avg | $56M | $61M |
| Low | $55M | $59M |
| High | $57M | $62M |
| Net Income Avg | $48M | $50M |
| Low | $48M | $49M |
| High | $49M | $51M |
| EPS Avg | $8.24 | $8.63 |
| Low | $8.19 | $8.41 |
| High | $8.33 | $8.80 |
| Analysts (Rev / EPS) | 2 / 3 | 2 / 3 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $35M | $36M | $36M | $37M | $39M | $40M |
| Low | $35M | $35M | $35M | $37M | $38M | $39M |
| High | $36M | $36M | $37M | $38M | $39M | $40M |
| EBITDA Avg | $14M | $15M | $15M | $15M | $16M | $16M |
| Low | $14M | $14M | $14M | $15M | $16M | $16M |
| High | $15M | $15M | $15M | $15M | $16M | $16M |
| EBIT Avg | $14M | $14M | $14M | $15M | $15M | $16M |
| Low | $14M | $14M | $14M | $15M | $15M | $16M |
| High | $14M | $15M | $15M | $15M | $16M | $16M |
| Net Income Avg | $12M | $12M | $12M | $12M | $13M | $13M |
| Low | $12M | $12M | $12M | $12M | $13M | $13M |
| High | $12M | $12M | $12M | $13M | $13M | $13M |
| EPS Avg | $2.08 | $2.09 | $2.04 | $2.13 | $2.21 | $2.25 |
| Low | $2.05 | $2.05 | $1.99 | $2.09 | $2.17 | $2.20 |
| High | $2.09 | $2.14 | $2.08 | $2.18 | $2.26 | $2.30 |
| Analysts (Rev / EPS) | 2 / 3 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 |